AGIOS PHARMACEUTICALS, INC. Operating Lease, Right-of-Use Asset, Amortization Expense
AGIOS PHARMACEUTICALS, INC. (AGIO) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $6.58 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2026-07-30
- AGIOS PHARMACEUTICALS, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-06-30 was $3.32M, a 7.96% increase year-over-year.
- AGIOS PHARMACEUTICALS, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-03-31 was $3.26M, a 7.95% increase year-over-year.
- AGIOS PHARMACEUTICALS, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-12-31 was $3.20M, a 7.90% increase year-over-year.
- AGIOS PHARMACEUTICALS, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-09-30 was $3.13M, a 7.77% increase year-over-year.
- AGIOS PHARMACEUTICALS, INC. operating lease, right-of-use asset, amortization expense for fiscal 2025 was $12.43M, a 7.76% increase from fiscal 2024.
- AGIOS PHARMACEUTICALS, INC. operating lease, right-of-use asset, amortization expense for fiscal 2024 was $11.53M, a 7.56% increase from fiscal 2023.
- AGIOS PHARMACEUTICALS, INC. operating lease, right-of-use asset, amortization expense for fiscal 2023 was $10.72M, a 7.25% increase from fiscal 2022.
- AGIOS PHARMACEUTICALS, INC. operating lease, right-of-use asset, amortization expense for fiscal 2022 was $9.99M, a 4.80% increase from fiscal 2021.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.32M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $6.58M 10-Q · filed 2026-07-30 | $9.78M derived: sum of 3 quarters · filed 2026-07-30 | $12.91M derived: sum of 4 quarters · filed 2026-07-30 |
| 2026-03-31 | $3.26M 10-Q · filed 2026-04-29 | $6.45M derived: sum of 2 quarters · filed 2026-04-29 | $9.59M derived: sum of 3 quarters · filed 2026-04-29 | $12.66M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-12-31 | $3.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $6.33M derived: sum of 2 quarters · filed 2026-02-12 | $9.41M derived: sum of 3 quarters · filed 2026-07-30 | $12.43M 10-K · filed 2026-02-12 |
| 2025-09-30 | $3.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $6.21M derived: sum of 2 quarters · filed 2026-07-30 | $9.23M 10-Q · filed 2025-10-30 | $12.19M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-06-30 | $3.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $6.09M 10-Q · filed 2026-07-30 | $9.06M derived: sum of 3 quarters · filed 2026-07-30 | $11.96M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | $3.02M 10-Q · filed 2026-04-29 | $5.98M derived: sum of 2 quarters · filed 2026-04-29 | $8.89M derived: sum of 3 quarters · filed 2026-04-29 | $11.74M derived: sum of 4 quarters · filed 2026-04-29 |
| 2024-12-31 | $2.96M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $5.87M derived: sum of 2 quarters · filed 2026-02-12 | $8.73M derived: sum of 3 quarters · filed 2026-02-12 | $11.53M 10-K · filed 2026-02-12 |
| 2024-09-30 | $2.91M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $5.76M derived: sum of 2 quarters · filed 2025-10-30 | $8.57M 10-Q · filed 2025-10-30 | $11.32M derived: sum of 4 quarters · filed 2026-02-12 |
| 2024-06-30 | $2.86M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-31 | $5.66M 10-Q · filed 2025-07-31 | $8.41M derived: sum of 3 quarters · filed 2026-02-12 | $11.12M derived: sum of 4 quarters · filed 2026-02-12 |
| 2024-03-31 | $2.80M 10-Q · filed 2025-05-01 | $5.56M derived: sum of 2 quarters · filed 2026-02-12 | $8.26M derived: sum of 3 quarters · filed 2026-02-12 | $10.91M derived: sum of 4 quarters · filed 2026-02-12 |
| 2023-12-31 | $2.75M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $5.46M derived: sum of 2 quarters · filed 2026-02-12 | $8.11M derived: sum of 3 quarters · filed 2026-02-12 | $10.72M 10-K · filed 2026-02-12 |
| 2023-09-30 | $2.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $5.36M derived: sum of 2 quarters · filed 2024-10-31 | $7.97M 10-Q · filed 2024-10-31 | $10.53M derived: sum of 4 quarters · filed 2025-02-13 |
| 2023-06-30 | $2.65M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $5.26M 10-Q · filed 2024-08-01 | $7.83M derived: sum of 3 quarters · filed 2025-02-13 | $10.34M derived: sum of 4 quarters · filed 2025-02-13 |
| 2023-03-31 | $2.61M 10-Q · filed 2024-05-02 | $5.17M derived: sum of 2 quarters · filed 2025-02-13 | $7.68M derived: sum of 3 quarters · filed 2025-02-13 | $10.17M derived: sum of 4 quarters · filed 2025-02-13 |
| 2022-12-31 | $2.56M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-13 | $5.08M derived: sum of 2 quarters · filed 2025-02-13 | $7.56M derived: sum of 3 quarters · filed 2025-02-13 | $9.99M 10-K · filed 2025-02-13 |
| 2022-09-30 | $2.51M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $5.00M derived: sum of 2 quarters · filed 2023-11-02 | $7.43M 10-Q · filed 2023-11-02 | $9.84M derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-06-30 | $2.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $4.92M 10-Q · filed 2023-08-03 | $7.33M derived: sum of 3 quarters · filed 2024-02-15 | $9.70M derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-03-31 | $2.44M 10-Q · filed 2023-05-04 | $4.84M derived: sum of 2 quarters · filed 2024-02-15 | $7.21M derived: sum of 3 quarters · filed 2024-02-15 | $9.56M derived: sum of 4 quarters · filed 2024-02-15 |
| 2021-12-31 | $2.41M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | $4.78M derived: sum of 2 quarters · filed 2024-02-15 | $7.12M derived: sum of 3 quarters · filed 2024-02-15 | $9.54M 10-K · filed 2024-02-15 |
| 2021-09-30 | $2.37M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $4.71M derived: sum of 2 quarters · filed 2022-11-03 | $7.13M 10-Q · filed 2022-11-03 | |
| 2021-06-30 | $2.34M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $4.76M 10-Q · filed 2022-08-04 | ||
| 2021-03-31 | $2.42M 10-Q · filed 2022-05-05 | |||
| 2020-12-31 | $8.98M 10-K · filed 2023-02-23 | |||
| 2019-12-31 | $8.53M 10-K · filed 2022-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |